ANN ARBOR, MI / ACCESSWIRE / June 15, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced it has signed a definitive agreement to acquire substantially all of the assets of Revo Squared LLC ("Revo").
Revo's innovative MicroView digital cytology platform will provide veterinarians with best-in-class image quality while providing the first in-clinic automated slide preparation system. Slide preparation is a critical part of cytology, and slide preparation errors are the number one reason cited by pathologists for being unable to read a slide. The MicroView platform improves practice workflow efficiency by automating the process to assure a consistent smear and stain in order to produce a readable slide.
Bill Campell, Chief Executive Officer of Revo Squared stated "We are excited to join the team at Zomedica; this deal will bring our MicroView product offering into the forefront of veterinary medicine. For the first time clinicians will be able to have hematology and cytology slides automatically smeared and stained inside a microscope, eliminating human error in slide preparation. Implementing MicroView in veterinary hospitals enhances diagnostics and reduces the wait time."
"We're excited to work with Bill and his colleague Negin Ghassemian as they join Zomedica as Vice President, Imaging Systems and Senior Director, Product Development," said Zomedica Chief Executive Officer, Larry Heaton, "They have done a great job of developing the MicroView system to this point, and we look forward to them leading the effort to integrate the MicroView system into the MyZomedica customer interface, commence manufacturing at our Zomedica manufacturing center in Alpharetta and bring it to market."
The Microview platform is intended for veterinary clinics of any size, especially those where a dedicated pathologist is not available on-site. The MicroView system allows veterinarians the option of reading the slide, and making a diagnosis themselves, or sending it digitally to the MicroView pathologist team for an expert second opinion.
"We're excited to reach a definitive agreement with Revo Squared and intend to close the transaction within 30 days." said Zomedica Vice President of Business Development and Strategic Planning, Greg Blair, "This furthers Zomedica's commitment to bring innovative technologies and tools to market that improve pet outcomes and pet parent satisfaction while also improving veterinary practice workflow efficiency and economics."
Based in Marietta, Georgia, Revo Squared has long been an innovator in veterinary imaging systems including Digital Cytology, ultrasound, and digital x-ray systems.
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Email Alerts: http://investors.zomedica.com
LinkedIn: https://www.linkedin.com/company/zomedica
Facebook: https://m.facebook.com/zomedica
Twitter: https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to American economic growth, demand for the Company's products, the Company's ability to produce and sell its products, our ability to successfully integrate and operate the PulseVet business, the sufficiency of our budgeted capital and operating expenditures, the cost, adequacy and availability of supplies required for our operations, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results, and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate and operate the Pulse Vet business, uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty regarding the cost, adequacy and availability of supplies required for our operations; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify, develop and/or achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations: risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
PCG Advisory Group Kirin Smith, President ksmith@pcgadvisory.com +1.646.823.8656
View source version on accesswire.com: https://www.accesswire.com/705057/Zomedica-to-Acquire-Assets-of-Innovative-Veterinary-Imaging-Company-Revo-Squared
Hexo Corp. said Friday its Zenabis Global Inc. cannabis cultivation unit has filed a petition with the Superior Court of Québec for protection under the Companies' Creditors Arrangement Act (CCAA) to restructure its business. Ernst & Young Inc. has been appointed as monitor to oversee the CCAA process. Hexo said the CCAA petition is limited to the Zenabis Group only and not for any of its other subsidiaries or parent company. Earlier this week Hexo said in a filing it'll reduce its workforce by
Anyone positioning their portfolio for a recession could be making a big mistake.
“We are exiting that regime, and it’s going to be bumpy,” said the famous Fed watcher Mohamed El-Erian of the world where central banks let the money flow.
When Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett speaks, Wall Street and investors wisely pay close attention. While riding Buffett's coattails has been a moneymaking strategy for decades, it's equally important to take note of the stocks that the world's most successful investor and his investing team are selling or avoiding. Thus far in 2022, Warren Buffett has overseen the aggressive selling of the following five stocks.
The Bitcoin carnage continues, as the cryptocurrency breaks $20,000 to trade at its lowest level since 2020.
Bitcoin’s price fell well below $19,783, the previous all-time high it notched in December 2017.
Already, very early signs of slowing demand and inflation are cropping up. If the economy averts all-out disaster, then stabilizing or declining rates would spur a market rebound.
AMD and Nvidia have been swallowed up in the bear market, with each stock declining at least 50%. Here's how to trade them now.
Retail stocks have taken a beating, but inflation, supply chain woes, and other cost concerns don't tell the full story.
‘Bitcoin has already broken down [and is] now seeing significant downside follow-through,’ says Katie Stockton of Fairlead Strategies. Bitcoin believer Yves Lamoureux of Lamoureux & Co., though, thinks ‘bitcoin is fine.’
Remember TINA? She’s the one everyone was talking about for the past few years, when it came to buying stocks. ‘There is no alternative,’ they said – pointing out that the near-zero interest rate policy has pushed bond yields down to nothing, and that the housing crisis of 2008 had left investors wary of the real estate market – and stocks were the highest returning game in town. Not anymore. The Federal Reserve has just cracked the whip on rate hikes, implementing a 0.75% increase to the benchm
A decline in earnings could be the next shoe to drop for investors. But it’s all a prelude to what may be the best buying opportunity in decades.
THE MONEYIST Dear Quentin, My boyfriend and I have been together seven years, and in that time I bought a house. I used my own savings and spent about $10,000 on renovations. My house is a three-bedroom family home, and the tenants cover most of my mortgage.
Bank stocks are dirt-cheap right now, and Citi in particular looks like a bargain. Watch the Fed’s stress-test results—and Warren Buffett’s purchases—to see what might be in store.
This year’s plunge in the stock market, unprecedented crash in the bond market, and surging inflation threaten new retirees in ways not seen before, he says. “The Jan. 1, 2022 retiree is retiring under conditions which have no certain precedent in the historical records I have used for my research,” Bengen tells MarketWatch. If the recent surge in inflation isn’t brought under control, he says, “we may witness history being made, and the first decline in the ‘safe’ withdrawal rate in more than 50 years.”
Since hitting their all-time closing highs, the widely followed Dow Jones Industrial Average, benchmark S&P 500, and growth stock-fueled Nasdaq Composite (NASDAQINDEX: ^IXIC) have respectively tumbled by 17%, 22%, and 33%. There's no question that the velocity and unpredictability of downward moves during a bear market can weigh on investors' psyche. This makes corrections and bear markets the opportune time to put your money to work.
Elon Musk is angry. Before getting to the reason for his anger, it should be noted that for more than a decade, from 2003 to almost 2013, the billionaire and Tesla pushed hard for the adoption of electric vehicles despite mockery from rivals and skepticism from financial markets and consumers. Musk and Tesla had, however, found an ear at the White House in the person of Barack Obama, newly elected in 2008.
Stocks' stomach-churning start to 2022 raises big questions for the next six months. Here's what you should know.
The cryptocurrency industry was built on swagger, enthusiasm and optimism. All three are in short supply these days, as losses and layoffs mount.
The major indexes sold off on recession fears, while Bitcoin broke another key level. Tesla rival BYD is near a buy point.